American Academy of Ophthalmology

R. Theodore Smith MD, PhD, professor of ophthalmology at the Icahn School of Medicine at Mount Sinai discusses new research to reduce the burden of AMD and how imaging can revolutionize the retina space.

David Brown, a retina specialist discusses how retina and diabetes specialists can coordinate care and education for their patients as well as the outlook for AMD/DME research.

In a phase 1 trial, patients in the femto-assisted crosslinking treatment arm had a more favorable outcome in the retention of corneal thickness, when compared to the conventional therapy group.

In a phase 2 study, a long-acting, implantable delivery system for ranibizumab allowed patients with wet age-related macular degeneration to go up to 15 months before requiring a refill.

Dilsher Dhoot, MD, discusses the avenues where future research for diabetic macular edema will focus

A novel subretinal implantation of a stem cell-based bioengineered patch may restore vision or prevent further vision loss.

Kahook Dual Blade intends to reduce intraocular pressure and the number of patient medications.

The retinal injection therapy could be capable of replacing damaged cells integral to eye vision.

Depression has been shown in research studies to correlate with the level of disability.

This new technology allows for smaller gauge with flow rate similar to that of the guillotine-based one.

The potential glaucoma and dry eye device administers 80% less topical treatment per dose.

Squalamine lactate, a topical eye drop, is studied as an add-on to anti-VEGF therapy to improve visual function.

An average 7,000 steps per day can cut glaucoma risk by up to 73%, researchers found.

The distractive spots floating through fields of vision may have finally met their match.

Researchers found racial and ethnic disparities in sites and types of injuries sustained in gunfire injuries to patients' eyes.

The multi-targeted inhibitor, a non-invasive eye drop, acts in a different way of treating the chronic disease.

The diagnostics of the disease is not only important for the initial evaluation, but also etiology and long-term management.

A study of Florida-based Veterans Affairs hospitals found trends among ocular conditions and chronic pain conditions.

As new diagnoses appear, etiology is understood better and treated better, resulting in a decrease of prevalence rates.

The smarthpone app Checkup is a preferred visual acuity test to the Amsler grid, according to study.

A study sub-analysis showed the anti-VEGF treatment maintained efficacy over longer intervals in a majority of patients.

A third review of TrueTear from Allergan showed the device is safe and efficacious in patients with dry eye.

A review of over 13,000 newly-diagnosed DME patients found that about 75% received no treatment in the first 28 days since diagnosis.

Vision loss patients may be 3 times as likely to suffer from major depressive symptoms than the general population.

The demand for diabetic-based health care is growing, and the future of imaging and treatment must follow guidelines.

The study compared bevacizumab, ranibizumab, and aflibercept for nAMD patients' eyes.

Studies based on data from the world's largest clinical specialty database corrected commonly-perceived trends in ophthalmology.

The grant will provide $35,000 to 6 inidivual researchers, who will use the 41 million-plus patient database IRIS Registry.

Luxturna, an injection therapy, helped genetic vision-loss patients navigate mazes in a phase 3 trial.

The treatment of wet age-related macular degeneration has come a long way in a short period of time. While it may take some explaining that injections in the eye are the best way to treat the condition now there is work being done to find better ways for the future.